Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | PAM | P19021 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3673142 | 1.00 | GAA (0.51) | GAAPAMHTTLMNAALDH1A1 | |
| SCHEMBL3673139 | 1.00 | GAA (0.51) | GAAPAMHTTLMNAALDH1A1 | |
| SCHEMBL8590081 | 0.85 | RECQL (0.47) | GAAPAMHTTLMNAALDH1A1 | |
| SCHEMBL1323308 | 0.84 | ALDH1A1 (0.54) | GAAHTTLMNAALDH1A1HDAC3 | |
| SCHEMBL1324251 | 0.84 | ALDH1A1 (0.54) | GAAHTTLMNAALDH1A1HDAC3 | |
| SCHEMBL1324704 | 0.84 | ALDH1A1 (0.54) | GAAHTTLMNAALDH1A1HDAC3 | |
| SCHEMBL1323312 | 0.84 | ALDH1A1 (0.54) | GAAHTTLMNAALDH1A1HDAC3 | |
| SCHEMBL1323311 | 0.84 | ALDH1A1 (0.54) | GAAHTTLMNAALDH1A1HDAC3 | |
| SCHEMBL1324252 | 0.84 | ALDH1A1 (0.54) | GAAHTTLMNAALDH1A1HDAC3 | |
| SCHEMBL5873328 | 0.81 | GAA (0.56) | GAAPAMHTTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1223923-B1 | UNSATURATED ARYL SULFONES FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | UNIV TEMPLE (US) | 2010-03-31 | — | — | EP | disclosed |
| US-7595347-B2 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | Temple University—Of the Commonwealth System of Higher Education (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1370253-B8 | USE OF ALPHA, BETA UNSATURATED ARYL SULFONES FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY | UNIV TEMPLE (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1370253-B1 | USE OF ALPHA, BETA UNSATURATED ARYL SULFONES FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY | UNIV TEMPLE (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1223923-A4 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | UNIV TEMPLE (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1370253-A4 | METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH $g(a), $g(b) UNSATURATED ARYL SULFONES | UNIV TEMPLE (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1027330-B1 | STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2004-12-08 | — | — | EP | disclosed |
| US-6828427-B1 | Oligomeric aminodiol-containing compounds, libraries thereof, and process of preparing the same | ISIS PHARMACEUTICALS, INC. | 2004-12-07 | — | — | US | disclosed |
| US-20040214903-A1 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | COSENZA STEPHEN C (US) | 2004-10-28 | — | — | US | disclosed |
| US-6767926-B1 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-07-27 | — | — | US | disclosed |
| US-20030060505-A1 | Method for protecting cells and tissues from ionizing radiation toxicity with alpha, beta unsaturated aryl sulfones | ONCONOVA THERAPEUTICS, INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2002069892-A2 | METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-1223923-A1 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6359013-B1 | BREAST AND PROSTATE CANCER; AFFECT THE MAPK SIGNAL TRANSDUCTION PATHWAY, THEREBY TUMOR CELL GROWTH; INHIBIT THE GROWTH OF TUMOR CELLS WITHOUT AFFECTING NORMAL CELLS; 4-FLUOROSTYRYL 4-BROMOBENZYL SULFONE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-03-19 | — | — | US | disclosed |
| US-20020022666-A1 | Styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-02-21 | — | — | US | disclosed |
| US-6316626-B1 | Amine compounds and combinatorial libraries comprising same | ISIS PHARMACEUTICALS, INC. | 2001-11-13 | — | — | US | disclosed |
| WO-2001026645-A1 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2001-04-19 | — | — | WO | disclosed |
| WO-2000059494-A1 | STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-1027330-A1 | STYRYL SULFONE ANTICANCER AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999018068-A1 | STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060505-A1 | Method for protecting cells and tissues from ionizing radiation toxicity with alpha, beta unsaturated aryl sulfones | ARSA, SULT2A1, CYP2S1 | GAA 1780/4885PAM 1821/4885HTT 3722/4885 |
| US-20040214903-A1 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | TOP1, TOP2A, PCNA | GAA 1602/4885PAM 3193/4885HTT 2917/4885 |
| US-20020022666-A1 | Styryl sulfone anticancer agents | BCL2, MCL1, BCL2A1 | GAA 4756/4885PAM 3546/4885HTT 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.